> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# OPDP Wants to Research Drug Name Interpretation
- URL: https://www.fdaweb.com/opdp-wants-to-research-drug-name-interpretation/
- Published: 2022-10-13T12:00:00.000Z
- Updated: 2026-09-14T18:02:57.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152966

The CDER Office of Prescription Drug Promotion (OPDP) is proposing research into how consumers and healthcare professionals interpret the proprietary names of drugs. OPDP says the results of the research will be useful to it in its role as one of several agency entities that evaluate proposed proprietary drug names.

OPDP says that in its evaluation it looks at whether names **(1)** overstate the efficacy or safety of the drug; **(2)** suggest drug indications that are not accurate; **(3)** suggest superiority without substantiation; or **(4)** are of a fanciful nature that misleadingly implies unique effectiveness or composition.

“It would be helpful in OPDP’s review of promotional implications of proprietary names for data on consumer and prescriber interpretation of proposed proprietary names to be more readily available for consideration,” a *Federal Register* [notice](https://public-inspection.federalregister.gov/2022-22301.pdf?ref=fdaweb.com) says. “The proposed research will use text analysis … to learn how consumer and primary care physician populations interpret prescription drug names, which will assist OPDP’s consideration of promotional implications.”